Clinical Trial Update: Safety Study of a Single IVT Injection of QPI-1007 in Chronic Optic Nerve Atrophy and Recent Onset NAION Patients [Phase 1]

View source ↗

Summary

This Phase 1 safety study evaluated a single intravitreal injection of QPI-1007 in patients with chronic optic nerve atrophy and recent onset non-arteritic ante…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-arteritic Anterior Ischemic Optic Neuropathy
• Optic Atrophy

Drugs mentioned

• QPI-1007 (p53-targeted siRNA)

Snippet

Sponsor: Quark Pharmaceuticals | Conditions: Optic Atrophy, Non-arteritic Anterior Ischemic Optic Neuropathy | Phase 1 | Status: COMPLETED